Abstract
Objectives: TG4001 (MVA-HPV-IL2) is based on the Modified Virus of Ankara (MVA) strain expressing E6 and E7 of Human Papillomavirus type 16 (HPV16) and human Interleukin-2 (IL-2). The efficacy of two different doses was tested in a randomized, phase II trial, conducted in patients with high-grade Cervical Intraepithelial Neoplasia (CIN2/3) related to HPV16.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
